RxElite, Inc. Refiles Registration Statement: Ability to Sell Under Prospectus Reinstated

MERIDIAN, ID , a developer, manufacturer, and marketer of specialty generic prescription drug products, announced today that it had filed a post effective amendment on Form S-1 to its previously suspended Registration Statement on Form SB-2 (File No. 333-146641) to incorporate certain required information related to its recent acquisition of assets of FineTech Laboratories, Ltd.

As a result of the filing made with and declared effective by the SEC on April 8, 2007, selling shareholders named in the prospectus may again commence sales in accordance with the prospectus.

This notice is provided for informational purposes only, and does not represent a solicitation or offer to buy or sell any security. Any offer will be made by means of a current prospectus only. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sales of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About RxElite, Inc.

RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), complex active pharmaceutical ingredients, and other specialty areas. www.RxElite.com

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

For more information: Corporate Information Ph: (208) 288-5550 Toll Free: (800) 414-1901 Fax: (208) 288-1191 Investor Relations Ric Tener PH: (208) 288-5550 Fax: (208) 288-1191 Email: Email Contact

RXElite (CE) (USOTC:RXEI)
Graphique Historique de l'Action
De Août 2024 à Sept 2024